Hilary Miller-Handley
LightNews LightNews
hilmill1113.bsky.social
Hilary Miller-Handley
@hilmill1113.bsky.social
260 followers 230 following 0 posts
Med-Peds ID Doctor interested in infections in transplant recipients.
Posts Replies Media Videos
Reposted by Hilary Miller-Handley
labwaggoner.bsky.social
Immune suppression sustained allograft acceptance requires PD1 inhibition of CD8+ T cells
doi.org/10.1093/jimm...
@cincyresearch.bsky.social @hilmill1113.bsky.social @jimmunol.bsky.social
Immune suppression sustained allograft acceptance requires PD1 inhibition of CD8+ T cells
Abstract. Organ transplant recipients require continual immune-suppressive therapies to sustain allograft acceptance. Although medication nonadherence is a
doi.org
January 24, 2025 at 4:06 PM
Reposted by Hilary Miller-Handley
thetxidjournal.bsky.social
So excited to have the Donor-Derived Infection Special Edition out - thanks to Stephanie Pouch and Karen Waller for being guest editors for this special edition!

onlinelibrary.wiley.com/toc/13993062...
Donor‐Derived Infections: Transplant Infectious Disease: Vol 26, No S1
Click on the title to browse this issue
onlinelibrary.wiley.com
December 4, 2024 at 10:21 PM
Reposted by Hilary Miller-Handley
science.org
Science’s 2024 Breakthrough of the Year is lenacapavir, an injectable drug that demonstrated remarkable success at preventing HIV infection with one shot every 6 months.

Learn more about this year's #BOTY and other big advances in science: scim.ag/3BrCtUn
Science’s 2024 Breakthrough of the Year is lenacapavir, an injectable drug that demonstrated remarkable success at preventing HIV infection with one shot every 6 months. The drug attaches to the lattice-like capsid proteins that shield the virus’s genetic material—a mechanism that could inspire other antivirals. Lenacapavir could help end the HIV/AIDS epidemic, but that will hinge on access for those who need it most.
December 12, 2024 at 7:02 PM